R
Rachel N. Grisham
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 103
Citations - 2178
Rachel N. Grisham is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 18, co-authored 69 publications receiving 1140 citations. Previous affiliations of Rachel N. Grisham include Cornell University & Duke University.
Papers
More filters
Journal ArticleDOI
Ovarian cancer, version 2.2020
Deborah K. Armstrong,Ronald D. Alvarez,Jamie N. Bakkum-Gamez,Lisa Barroilhet,Kian Behbakht,Andrew Berchuck,Lee-may Chen,Mihaela C. Cristea,Maria DeRosa,Eric L. Eisenhauer,David M. Gershenson,Heidi J. Gray,Rachel N. Grisham,Ardeshir Hakam,Angela Jain,Amer Karam,Gottfried E. Konecny,Charles A. Leath,Joyce F. Liu,Haider Mahdi,Lainie P. Martin,Daniela Matei,Michael T. McHale,Karen McLean,David Miller,David M. O'Malley,Sanja Percac-Lima,Elena Ratner,Steven W. Remmenga,Roberto Vargas,Theresa L. Werner,Emese Zsiros,Jennifer L. Burns,Anita M. Engh +33 more
Journal ArticleDOI
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A. Konstantinopoulos,Barbara M. Norquist,Christina Lacchetti,Deborah K. Armstrong,Rachel N. Grisham,Paul J. Goodfellow,Elise C. Kohn,Douglas A. Levine,Joyce F. Liu,Karen H. Lu,Dorinda Sparacio,Christina M. Annunziata +11 more
TL;DR: Recommendations are made that first- or second-degree blood relatives of a patient with ovarian cancer with a known germline pathogenic cancer susceptibility gene variant should be offered individualized genetic risk evaluation, counseling, and genetic testing.
Journal ArticleDOI
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Rachel N. Grisham,Gopa Iyer,Karuna Garg,Deborah DeLair,David M. Hyman,Qin Zhou,Alexia Iasonos,Michael F. Berger,Fanny Dao,David R. Spriggs,Douglas A. Levine,Carol Aghajanian,David B. Solit +12 more
TL;DR: This study sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer.
Journal ArticleDOI
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Tara Soumerai,Mark T.A. Donoghue,Chaitanya Bandlamudi,Preethi Srinivasan,Matthew T. Chang,Matthew T. Chang,Dmitriy Zamarin,Karen Cadoo,Karen Cadoo,Rachel N. Grisham,Rachel N. Grisham,Roisin E. O'Cearbhaill,Roisin E. O'Cearbhaill,William P. Tew,William P. Tew,Jason A. Konner,Jason A. Konner,Martee L. Hensley,Martee L. Hensley,Vicky Makker,Vicky Makker,Paul Sabbatini,Paul Sabbatini,David R. Spriggs,David R. Spriggs,Tiffany A. Troso-Sandoval,Tiffany A. Troso-Sandoval,Alexandra Snyder Charen,Claire F. Friedman,Claire F. Friedman,Mila Gorsky,Mila Gorsky,Sarah J. Schweber,Sarah J. Schweber,Sumit Middha,Rajmohan Murali,Sarah Chiang,Kay J. Park,Robert A. Soslow,Marc Ladanyi,Bob T. Li,Bob T. Li,Jennifer J. Mueller,Jennifer J. Mueller,Britta Weigelt,Ahmet Zehir,Michael F. Berger,Nadeem R. Abu-Rustum,Nadeem R. Abu-Rustum,Carol Aghajanian,Carol Aghajanian,Deborah DeLair,David B. Solit,Barry S. Taylor,David M. Hyman,David M. Hyman +55 more
TL;DR: Prospective clinical sequencing of advanced endometrial cancer can help refine prognosis and aid treatment decision making by simultaneously detecting microsatellite status, germline predisposition syndromes, and potentially actionable mutations.
Journal ArticleDOI
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N. Grisham,Brooke E. Sylvester,Helen Won,Gregory McDermott,Deborah DeLair,Ricardo Ramirez,Zhan Yao,Ronglai Shen,Fanny Dao,Faina Bogomolniy,Vicky Makker,Evis Sala,Tara Soumerai,David M. Hyman,Nicholas D. Socci,Agnes Viale,David M. Gershenson,John H. Farley,Douglas A. Levine,Neal Rosen,Michael F. Berger,David R. Spriggs,Carol Aghajanian,David B. Solit,Gopa Iyer +24 more
TL;DR: These findings, coupled with the observation that a subset of patients with recurrent LGS ovarian cancer experienced dramatic and durable responses to MEK inhibitor therapy, support additional clinical studies of MEK inhibitors in this disease.